Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer

被引:205
作者
Wojtowicz-Praga, S
Torri, J
Johnson, M
Steen, V
Marshall, J
Ness, E
Dickson, R
Sale, M
Rasmussen, HS
Chiodo, TA
Hawkins, MJ
机构
[1] Georgetown Univ, Dept Med, Div Med Oncol, Washington, DC USA
[2] Georgetown Univ, Dept Med, Div Rheumatol, Washington, DC USA
[3] Georgetown Univ, Dept Cell Biol & Clin Pharmacol, Washington, DC USA
[4] British Biotech Inc, Annapolis, MD USA
关键词
D O I
10.1200/JCO.1998.16.6.2150
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This phase I study was performed to evaluate the safety and pharmacokinetics of escalating doses of Marimastat (British Biatech, Inc, Oxford, United Kingdom) in patients with advanced malignancies and to determine the phase II recommended dose to be used in subsequent studies. Patients and Methods: A standard phase I design was used in this study in which consecutive groups of three patients were treated with escalating doses of the study drug. Marimastat was administered orally at 25, 50, or 100 mg twice daily to consecutive groups of patients with advanced lung cancer. An additional three patients were added at the highest dose studied (100 mg orally twice daily) to assess whether the inflammatory polyarthitis observed at. that dose level can be prevented by a concurrent administration of nonsteroidal antiinflammatory drugs (NSAIDS) and/or low-dose corticosteroids. Blood was drawn for safety monitoring, pharmacokinetic analysis, and plasma levels of metalloproteinase (MMP)-2 and MMP-9 (determined by zymography). A total of 12 patients were studied. Results: The most significant toxicity at the highest dose studied (100 mg orally twice daily) was a symptomatic inflammatory polyarthritis that persisted for up to 8 weeks after discontinuation of the study drug and was dose-limiting. The estimated plasma elimination half-life of Marimastat was 4 to 5 hours, The mean maximum concentration (C-max) at a reasonably well-tolerated dose (50 mg orally twice daily) was 196 ng/mL and was reached within 1 to 2 hours (T-max) after administration. Areas under the curve (AUC) tended to correlate with the dose of Marimastat. Zymographic analysis of peripheral-blood ratios of activated proenzymatic forms of MMP-2 and -9 did not show any consistent patterns of change in MMP levels or in a degree of their activation during the course of treatment. Conclusion: Marimastat was well absorbed from the gastrointestinal tract, with high levels of the study drug detected in plasma within hours after drug administration. Plasma concentrations of Marimastat achieved at dose levels 2 and 3 (50 mg and 100 mg orally twice daily) were substantially higher than those required for MMP inhibition in vitro. The dose limiting toxicity (DLT) was severe inflammatory polyarthritis, which seemed to be a cumulative toxicity. (C) 1998 by American Society of Clinical Oncology.
引用
收藏
页码:2150 / 2156
页数:7
相关论文
共 22 条
  • [1] ASSOCIATION OF MMP-2 ACTIVATION POTENTIAL WITH METASTATIC PROGRESSION IN HUMAN BREAST-CANCER CELL-LINES INDEPENDENT OF MMP-2 PRODUCTION
    AZZAM, HS
    ARAND, G
    LIPPMAN, ME
    THOMPSON, EW
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (21) : 1758 - 1764
  • [2] HUMAN MACROPHAGE METALLOELASTASE - GENOMIC ORGANIZATION, CHROMOSOMAL LOCATION, GENE LINKAGE, AND TISSUE-SPECIFIC EXPRESSION
    BELAAOUAJ, A
    SHIPLEY, JM
    KOBAYASHI, DK
    ZIMONJIC, DB
    POPESCU, N
    SILVERMAN, GA
    SHAPIRO, SD
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (24) : 14568 - 14575
  • [3] BOASBERG P, 1996, P AN M AM SOC CLIN, V15, P258
  • [4] ASSOCIATION BETWEEN EXPRESSION OF ACTIVATED 72-KILODALTON GELATINASE AND TUMOR SPREAD IN NON-SMALL-CELL LUNG-CARCINOMA
    BROWN, PD
    BLOXIDGE, RE
    STUART, NSA
    GATTER, KC
    CARMICHAEL, J
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (07) : 574 - 578
  • [5] THE C-TERMINAL REGION OF MEMBRANE TYPE MATRIX METALLOPROTEINASE IS A FUNCTIONAL TRANSMEMBRANE DOMAIN REQUIRED FOR PRO-GELATINASE-C ACTIVATION
    CAO, J
    SATO, H
    TAKINO, T
    SEIKI, M
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (02) : 801 - 805
  • [6] INTERSTITIAL COLLAGENASE IS REQUIRED FOR ANGIOGENESIS IN-VITRO
    FISHER, C
    GILBERTSONBEADLING, S
    POWERS, EA
    PETZOLD, G
    POORMAN, R
    MITCHELL, MA
    [J]. DEVELOPMENTAL BIOLOGY, 1994, 162 (02) : 499 - 510
  • [7] WHAT IS THE EVIDENCE THAT TUMORS ARE ANGIOGENESIS DEPENDENT
    FOLKMAN, J
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (01): : 4 - 6
  • [8] FRIDMAN R, 1995, CANCER RES, V55, P2548
  • [9] ELECTROPHORETIC ANALYSIS OF PLASMINOGEN ACTIVATORS IN POLYACRYLAMIDE GELS CONTAINING SODIUM DODECYL-SULFATE AND COPOLYMERIZED SUBSTRATES
    HEUSSEN, C
    DOWDLE, EB
    [J]. ANALYTICAL BIOCHEMISTRY, 1980, 102 (01) : 196 - 202
  • [10] LEVY AT, 1991, CANCER RES, V51, P439